Patents by Inventor Yingying HU

Yingying HU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250067125
    Abstract: The present invention relates to a nonmetallic unbonded flexible riser for deep-sea mining and a manufacturing method thereof, wherein the riser includes a lining layer, an internal pressure resistant reinforcing layer, a first anti-wear layer, a first compensation reinforcing layer, a second anti-wear layer, a second compensation reinforcing layer, a third anti-wear layer, a framework layer, a isolation layer, a first tensile reinforcing layer, a fourth anti-wear layer, a second tensile reinforcing layer and an outer coating layer which are sequentially arranged from inside to outside, wherein unbonded connection between adjacent layers is adopted. The present invention may ensure the continuous transportation of the mineral and the seawater inside the flexible mixed transportation pipe, adapt to the severe marine environment and loading condition, and ensure the safety of mining work.
    Type: Application
    Filed: May 30, 2024
    Publication date: February 27, 2025
    Inventors: Yingying WANG, Haibo Sun, Chuanbo Cong, Liwei Li, Lusheng Jia, Zhaojun LV, Ke Zhang, Yufang Li, Wei Kong, Zeqing Lin, Hao Yu, Xingwei Li, Yangdong Hu, Guoan Shen
  • Patent number: 12230191
    Abstract: Systems and methods are described herein to control brightness based on image content or other inputs to a display system. A dual-control system may integrate both slow control operations and fast control operations into a cohesive brightness management system. By using both shorter-term (e.g., fast control) and longer-term (e.g., slow control) brightness adjustment operations, the electronic device may quickly respond to high luminance and high brightness situations that may cause burn-in into the display, image artifacts, or other damage. Responding quickly to these high consumption situations may prevent damage or perceivable upset to an ongoing process, among other benefits.
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: February 18, 2025
    Assignee: Apple Inc.
    Inventors: Wanqing Xin, Yang Xu, Mohammad Ali Jangda, Jenny Hu, Koorosh Aflatooni, Giovanni Corradini, Martin Kocicka, Alexey Kornienko, Asha G Karvaje, Aishwarya Prem Renu, Andrew D Pangborn, Chaohao Wang, Yingying Tang, Arthur L Spence, Mahesh B Chappalli
  • Publication number: 20250030509
    Abstract: The present disclosure provides a method and device for performing signal communication based on a levitated particle. In one example, the method includes: preparing a levitated state of the particle; regulating and measuring a net charge quantity carried by the levitated particle; calibrating electromagnetic response characteristics of the levitated particle; applying an electromagnetic communication signal; obtaining and demodulating the electromagnetic communication signal.
    Type: Application
    Filed: May 25, 2023
    Publication date: January 23, 2025
    Applicants: ZHEJIANG LAB, ZHEJIANG UNIVERSITY
    Inventors: Huizhu HU, Zhenhai FU, Xiaowen GAO, Xingfan CHEN, Nan LI, Cheng LIU, Zhiming CHEN, Jinsheng XU, Shaochong ZHU, Yingying WANG, Peitong HE
  • Publication number: 20240247041
    Abstract: The present disclosure discloses IL-2 mutants and uses thereof. More specifically, the disclosure provides IL-2 mutants and corresponding fusion proteins, conjugates, nucleic acid fragments, vectors, host cells, methods for preparing the mutants or fusion proteins, IL-2 mutants or fusion proteins prepared according to the methods, pharmaceutical compositions, pharmaceutical uses, methods for treating diseases, and methods for preferentially stimulating regulatory T cells. Compared to wild-type IL-2, the IL-2 mutants of the present disclosure have higher Tm values and improved stability; alternatively, the IL-2 mutants of the present disclosure have an increased yield or changed binding activity to the IL-2R?? complexes compared to wild-type IL-2.
    Type: Application
    Filed: April 4, 2024
    Publication date: July 25, 2024
    Inventors: Yingying HU, Zhuoxiao Cao, Renhong Tang, Hu Ge, Yayuan Fu, Jinsheng Ren
  • Publication number: 20240209051
    Abstract: The present disclosure discloses IL-2 mutants and uses thereof. More specifically, the disclosure provides IL-2 mutants and corresponding fusion proteins, conjugates, nucleic acid fragments, vectors, host cells, methods for preparing the mutants or fusion proteins, IL-2 mutants or fusion proteins prepared according to the methods, pharmaceutical compositions, pharmaceutical uses, methods for treating diseases, and methods for preferentially stimulating regulatory T cells. Compared to wild-type IL-2, the IL-2 mutants of the present disclosure have higher Tm values and improved stability; alternatively, the IL-2 mutants of the present disclosure have an increased yield or changed binding activity to the IL-2R?? complexes compared to wild-type IL-2.
    Type: Application
    Filed: December 20, 2023
    Publication date: June 27, 2024
    Inventors: Yingying HU, Zhuoxiao CAO, Renhong TANG, Hu GE, Yayuan FU, Jinsheng REN
  • Patent number: 12018078
    Abstract: Provided are a murine or fully human monoclonal antibody targeting SEMA4D and a preparation method therefor, wherein the antibody binds to the SEMA4D antigen and has activities such as combating tumors.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: June 25, 2024
    Assignee: JIANGSU HUAIYU PHARMACEUTICAL CO., LTD.
    Inventors: Yingying Hu, Xiaodan Cao, Zihan Jin, Lina Wang, Yuandong Wang, Xiaohui Shao, Shaoping Hu, Mingming Pan, Yan Liu, Wei Shao, Yanyan Li, Xiaoxuan Lan, Ying Gu, Siran Zhu, Lile Liu, Qing Duan
  • Publication number: 20230410953
    Abstract: The present invention discloses a method for constructing and optimizing a molecular structure model of lignite, comprising: collecting and processing a lignite sample, analyzing a lignite experimental sample, calculating the number of carbon atoms in lignite and the number of carbon atoms in other parameters, obtaining the sizes of aromatic clusters, and determining the composition features and number of aromatic structural units in lignite; calculating the total number of carbon atoms and the number of aliphatic carbon atoms in lignite; obtaining the categories and number of oxygen-containing functional groups in lignite based on the contents of aromatic hydrocarbon, aliphatic hydrocarbon and various oxygen-containing functional groups, and designing the structural forms of nitrogen and sulfur; constructing a molecular structure model of lignite.
    Type: Application
    Filed: September 5, 2023
    Publication date: December 21, 2023
    Inventors: Qingtao Zhang, Xueyang Xing, Yingying Hu, Gang Zhou, Bo Li, Jianjun Shen, Mingming Fu, Xiaofei Li, Lanjuan Xu, Shuai Du, Xinlei Jia, Zhenjiang Yin, Qianqian Zhang, Jie Zang, Qing Cao, Hui Ma, Lei Zhao
  • Publication number: 20230265148
    Abstract: The present disclosure discloses IL-2 mutants and uses thereof. More specifically, the disclosure provides IL-2 mutants and corresponding fusion proteins, conjugates, nucleic acid fragments, vectors, host cells, methods for preparing the mutants or fusion proteins, IL-2 mutants or fusion proteins prepared according to the methods, pharmaceutical compositions, pharmaceutical uses, methods for treating diseases, and methods for preferentially stimulating regulatory T cells. Compared to wild-type IL-2, the IL-2 mutants of the present disclosure have higher Tm values and improved stability; alternatively, the IL-2 mutants of the present disclosure have an increased yield or changed binding activity to the IL-2R?? complexes compared to wild-type IL-2.
    Type: Application
    Filed: September 3, 2021
    Publication date: August 24, 2023
    Inventors: Yingying HU, Zhuoxiao CAO, Renhong TANG, Hu GE, Yayuan FU, Jinsheng REN
  • Publication number: 20230073534
    Abstract: Disclosed herein are chimeric blastocysts, such as chimeric blastocysts derived from a host blastocyst from a first mammalian species and having donor pluripotent stem cells from a second mammalian species, wherein the donor pluripotent stem cells have reduced expression or reduced biological activity of one or more proteins in the TLR/NF-kB signaling pathway or the p53 pathway. Methods of preparing chimeric blastocysts and methods of obtaining mammalian organs and tissues are also provided.
    Type: Application
    Filed: January 21, 2021
    Publication date: March 9, 2023
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jun WU, Canbin ZHENG, Yingying HU
  • Publication number: 20220073608
    Abstract: Provided are a murine or fully human monoclonal antibody targeting SEMA4D and a preparation method therefor, wherein the antibody binds to the SEMA4D antigen and has activities such as combating tumors.
    Type: Application
    Filed: July 15, 2019
    Publication date: March 10, 2022
    Inventors: Yingying HU, Xiaodan CAO, Zihan JIN, Lina WANG, Yuandong WANG, Xiaohui SHAO, Shaoping HU, Mingming PAN, Yan LIU, Wei SHAO, Yanyan LI, Xiaoxuan LAN, Ying GU, Siran ZHU, Lile LIU, Qing DUAN
  • Publication number: 20210347873
    Abstract: A BLyS antibody, preparation method therefor and application thereof, the BLyS antibody comprising one or more of CDR1, CDR2 and CDR3 of a heavy chain variable region of the BLyS antibody, and/or one or more of CDR1, CDR2 and CDR3 of a light chain variable region of the BLyS antibody. An amino acid sequence of the antibody is shown in a sequence listing. The BLyS antibody has a high affinity, and may observably and effectively seal a BLyS protein at a protein level and a cell level, and prevent the BLyS protein from binding to a receptor. The BLyS antibody lacks a cross-reaction with homologous protein antigens such as human APRIL, and enjoys good biological activity. The BLyS antibody may inhibit the proliferation of human BLyS-induced mouse B cells and may therefore be used for preparing a drug for preventing or treating diseases associated with BLyS expression or dysfunction.
    Type: Application
    Filed: July 5, 2017
    Publication date: November 11, 2021
    Inventors: Xiaodan CAO, Yingying HU, Fang REN, Shiyong GONG, Jing GONG, Qiang LV, Hongzhuan GU, Beilei SHI, Xiaohui SHAO, Xiaofen LV, Stewart LEUNG, Lile LIU
  • Patent number: D1023629
    Type: Grant
    Filed: November 21, 2021
    Date of Patent: April 23, 2024
    Assignee: Ningbo Jisheng Technology Co., LTD
    Inventor: Yingying Hu
  • Patent number: D1024086
    Type: Grant
    Filed: September 7, 2022
    Date of Patent: April 23, 2024
    Assignee: Ningbo Jiesheng Technology Co., Ltd.
    Inventor: Yingying Hu
  • Patent number: D1032579
    Type: Grant
    Filed: September 7, 2022
    Date of Patent: June 25, 2024
    Inventor: Yingying Hu